Edition:
India

Vectura Group PLC (VEC.L)

VEC.L on London Stock Exchange

72.50GBp
18 Apr 2019
Change (% chg)

0.20 (+0.28%)
Prev Close
72.30
Open
70.60
Day's High
73.10
Day's Low
70.60
Volume
896,288
Avg. Vol
928,686
52-wk High
107.80
52-wk Low
65.85

Latest Key Developments (Source: Significant Developments)

Vectura Group PLC 2018 Preliminary Results
Tuesday, 26 Mar 2019 

March 26 (Reuters) - Vectura Group PLC ::VECTURA GROUP PLC 2018 PRELIMINARY RESULTS.  Full Article

Vectura Says VR475 Fails Key Goal In Late-Stage Study
Monday, 26 Nov 2018 

Nov 26 (Reuters) - Vectura Group Plc ::RESULTS FOR VR475 IN SEVERE UNCONTROLLED ASTHMA.PHASE III STUDY OF VR475 IN ADULT AND ADOLESCENT PATIENTS WITH SEVERE UNCONTROLLED ASTHMA DID NOT MEET ITS PRIMARY ENDPOINT.VECTURA HAS DECIDED TO NOT PURSUE FURTHER DEVELOPMENT AND PARTNERING OF VR475.ASSET FOR VR475 PROGRAMME TO BE FULLY IMPAIRED IN CURRENT FY, RESULTING IN NEGATIVE IMPACT ON PRETAX LOSS OF £40M.WITH RESPECT TO 2019, EXPECTS NET IMPACT TO EBITDA OF REVENUE, RESEARCH AND DEVELOPMENT COST MOVEMENTS, TO BE BROADLY NEUTRAL.  Full Article

Vectura Group Says Flutiform Receives Positive Opinion In Europe
Friday, 9 Nov 2018 

Nov 9 (Reuters) - Vectura Group PLC ::VECTURA GROUP PLC - FLUTIFORM RECEIVES POSITIVE OPINION IN EUROPE.VECTURA GROUP PLC - FLUTIFORM RECEIVES POSITIVE OPINION IN EUROPE FOR TREATMENT OF CHILDREN WITH ASTHMA.  Full Article

Vectura Confirms Appointment Of Paul Fry As CFO from Oct. 22
Monday, 22 Oct 2018 

Oct 22 (Reuters) - Vectura Group PLC ::VECTURA GROUP - CONFIRM APPOINTMENT OF PAUL FRY AS CFO AND EXECUTIVE DIRECTOR OF COMPANY WITH EFFECT FROM 22 OCTOBER 2018.  Full Article

Vectura Says To Date Revenues Are In Line With Its Expectations For Full Year
Thursday, 17 May 2018 

May 17 (Reuters) - Vectura Group PLC ::BASED ON OVERALL TRADING PERFORMANCE TO DATE IN 2018 BOARD CONFIRMS THAT GROUP'S REVENUES ARE IN LINE WITH ITS EXPECTATIONS FOR FULL YEAR.  Full Article

Vectura Group Posts FY Reported Revenue Of 148.0 Mln Pounds‍​
Wednesday, 21 Mar 2018 

March 21 (Reuters) - Vectura Group Plc ::FULL YEAR REPORTED REVENUE OF £148.0 MILLION, IN LINE WITH BOARD EXPECTATIONS (REPORTED 9M 2016: £126.5 MILLION)‍​.2016 FULL-YEAR PROFORMA REVENUE WAS £183.6 MILLION‍​.MAINTAINS 2018 REVENUE GROWTH EXPECTATIONS AND REITERATES PREVIOUSLY-REDUCED RESEARCH AND DEVELOPMENT INVESTMENT GUIDANCE RANGE OF £55 MILLION TO £65 MILLION FOR YEAR ‍​.2017 UNDERLYING REVENUE WAS £131.4 MILLION; +4.0% DRIVEN BY THE GROUP'S KEY-INHALED PRODUCTS.ENDED THE YEAR WITH A CLOSING CASH BALANCE OF £103.7 MILLION (31 DECEMBER 2016: £92.5 MILLION).FY ADJUSTED EBITDA WAS AHEAD OF EXPECTATIONS AT £25.8 MILLION PROFIT (REPORTED 9M 2016: £34.1 MILLION PROFIT).NOTWITHSTANDING DISAPPOINTING DELAYS CO SEEN FOR VR315 (US) GENERIC ADVAIR PROGRAMME, CONTINUE TO SEE SUBSTANTIAL VALUE IN DEVELOPMENT OF COMPLEX INHALED GENERICS‍​.LOOK FORWARD TO A SERIES OF SIGNIFICANT NEWS FLOW CATALYSTS DURING 2018.  Full Article

Vectura Group Anticipates FY 2017 Revenue In Line With Board's Expectations
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Vectura Group Plc ::FULL YEAR 2017 REVENUE ANTICIPATED TO BE IN LINE WITH BOARD'S EXPECTATIONS.FLUTIFORM PRODUCT SUPPLY REVENUE IN H2 2017 IS IN LINE WITH GUIDANCE PROVIDED.FLUTIFORMQ3 1 IN-MARKET NET SALES WERE EUR 47.8 MILLION 2 , UP 12% AT CONSTANT EXCHANGE RATES.ULTIBRO Q3 1 NET SALES OF $101 MILLION, WITH 18% GROWTH IN EUROPE YEAR-ON-YEAR.ROYALTIES FROM GSK ELLIPTA® PRODUCTS ACHIEVED £9 MILLION ANNUAL CAP IN Q3.WERE CURRENT EXCHANGE RATES TO CONTINUE THROUGH 2018, STERLING REPORTED REVENUES WOULD BE REDUCED BY APPROXIMATELY £5.0 MILLION.RESEARCH AND DEVELOPMENT COSTS IN 2018 ARE EXPECTED TO REDUCE TO £55 MILLION - £65 MILLION (PREVIOUS 2018 GUIDANCE: £65 MILLION - £75 MILLION).  Full Article

Vectura Group posts HY revenue of 78.8 million pounds
Wednesday, 6 Sep 2017 

Sept 6 (Reuters) - Vectura Group Plc :H1 PRETAX LOSS 44.5 MILLION STG.HY REVENUE 78.8 MILLION POUNDS VERSUS 73.9 MILLION POUNDS A YEAR AGO.HY RECURRING REVENUE PERCENT OF TOTAL REVENUE 90.1 PERCENT VERSUS 76.2 PERCENT A YEAR AGO.HY RECURRING REVENUE 71 MILLION POUNDS VERSUS 56.3 MILLION POUNDS A YEAR AGO.DETAILED REVIEW OF PRIORITIES FOR RESEARCH AND DEVELOPMENT PROGRAMMES IN 2017 UNDERTAKEN AND EXPENDITURE FOR FY IS NOW EXPECTED TO BE LOWER, AT £60 MILLION - £70 MILLION."SINCE CRL, VECTURA SUPPORTED HIKMA IN CONSTRUCTIVE DIALOGUE WITH FDA AND A NUMBER OF QUESTIONS RAISED HAVE NOW BEEN CLARIFIED AND RESOLVED"."EXPECTS TO BE ABLE TO CONFIRM REGULATORY TIMETABLE BEFORE END OF 2017".IN LINE WITH BOARD'S EXPECTATIONS, REMAINS ON TRACK TO DELIVER ORIGINAL £10 MILLION TARGET ANNUAL COST SYNERGIES BY 2018 WITH MAJORITY REALISED IN 2017.FURTHER ANNUAL NON-HEADCOUNT COST SYNERGY OPPORTUNITIES OF £1 MILLION - £2 MILLION FROM 2018 HAVE BEEN IDENTIFIED."THERE IS PRODUCTIVE DIALOGUE AND PROGRESS BEING MADE WITH FDA FOLLOWING RECEIPT OF MAJOR CRL FOR VR315 ADVAIR GENERIC IN US, CONCLUDING NUMBER OF OPEN QUESTIONS" - CEO.MAINTAINS PREVIOUS GUIDANCE OF £65 MILLION - £75 MILLION ANNUAL RESEARCH AND DEVELOPMENT EXPENDITURE FOR 2018.  Full Article

Vectura announces ANDA filing for US generic version of Advair Diskus
Thursday, 17 Aug 2017 

Aug 17 (Reuters) - VECTURA GROUP PLC ::CONFIRMS STATEMENT MADE BY PARTNER HIKMA IN RESPECT OF ANDA FILING FOR A US GENERIC VERSION OF ADVAIR DISKUS.  Full Article

Vectura says global development agreement with Dynavax
Wednesday, 16 Aug 2017 

Aug 16 (Reuters) - VECTURA GROUP PLC ::GLOBAL DEVELOPMENT AGREEMENT WITH DYNAVAX.VECTURA'S AKITA SMART NEBULISER TO BE USED BY DYNAVAX TO DELIVER DV281.VECTURA ELIGIBLE TO RECEIVE MODEST MILESTONES, DEVELOPMENT SERVICES REVENUES.DOES NOT EXPECT MATERIAL IMPACT ON R&D EXPENDITURE WHICH REMAINS WITHIN PREVIOUS ANNUAL GUIDANCE RANGE OF £65-75M FOR 2017 AND 2018.  Full Article